Early response of ceftaroline fosamic in the treatment of soft-tissue infections

Expert Review of Clinical Pharmacology

Volumn 5, Issue 5, 2012, Pages 509-512

  Giuliano, Christopher ^a   Kale Pradhan, Pramodini B ^a   Johnson, Leonard B ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ceftaroline; skin and soft tissue infections; vancomycin

Indexed keywords

AZTREONAM; CEFTAROLINE FOSAMIL; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED PNEUMONIA; DRUG COST; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; AZTREONAM; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; ENDPOINT DETERMINATION; HUMANS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SOFT TISSUE INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84868524683     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.50     Document Type: Review

References (15)

1. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51(6), 641-650 (2010).
2. Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int. J. Antimicrob. Agents 34(Suppl. 1), S2-S7 (2009).
3. Stevens DL, Bisno AL, Chambers HF et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41(10), 1373-1406 (2005).
4. Moran GJ, Krishnadasan A, Gorwitz RJ et al.; EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).
5. Wilcox MH, Corey GR, Talbot Gh, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob. Chemother. 65(Suppl. 4), iv53-iv65 (2010).
6. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl. 4), iv41-iv51 (2010).
7. Snodgrass WR, Anderson T. Sulphanilamide in the treatment of Erysipelas. Br. Med. J. 2(4014), 1156-1159 (1937).
8. Snodgrass WR, Anderson T. Prontosil in Erysipelas. Br. Med. J. 2(3993), 101-104 (1937).
9. Friedland HD, O'Neal T, Biek D et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two Phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 56(5), 2231-2236 (2012).
10. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53(11), 4712-4717 (2009).
11. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51(9), 3397-3400 (2007).
12. Cottanoud P, Acosta F, Biek D, Cottagnoud M, Leib S. Ceftaroline fosamil against penicillin-sensitive and penicillin-resistant Streptococcus pneumoniae in an experimental meningitis model. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Boston, MA, USA, 12-15 September 2010.
13. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl. 4), iv67-iv71 (2010).
14. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 52(9), 1156-1163 (2011).
15. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl. 4), S341-S345 (2004).